Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 1.00 |
| ▸ | AKT2 | P31751 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998534 | 0.85 | AKT1 (0.74) | AKT1AKT2L3MBTL1KDM4ELMNA | |
| SCHEMBL14278952 | 0.81 | AKT1 (0.68) | AKT1AKT2L3MBTL1KDM4ELMNA | |
| SCHEMBL9247740 | 0.80 | AKT1 (0.66) | AKT1AKT2TDP1KMT2AALDH1A1 | |
| SCHEMBL13950894 | 0.80 | KDM4E (0.78) | AKT1AKT2L3MBTL1KDM4ELMNA | |
| SCHEMBL21998533 | 0.79 | AKT1 (0.66) | AKT1AKT2L3MBTL1KDM4ELMNA | |
| SCHEMBL12710373 | 0.79 | AKT1 (0.63) | AKT1AKT2L3MBTL1KDM4ELMNA | |
| SCHEMBL24590007 | 0.78 | KDM4E (0.75) | AKT1AKT2L3MBTL1KDM4ELMNA | |
| SCHEMBL22769174 | 0.78 | KDM4E (0.75) | AKT1AKT2L3MBTL1KDM4ELMNA | |
| SCHEMBL22769176 | 0.78 | KDM4E (0.75) | AKT1AKT2L3MBTL1KDM4ELMNA | |
| SCHEMBL13726198 | 0.78 | KDM4E (0.75) | AKT1AKT2L3MBTL1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148682-A1 | AKT ISOZYME-SPECIFIC COVALENT INHIBITORS DERIVED FROM REDOX-SIGNALING LIPIDS | CORNELL UNIVERSITY | 2020-05-14 | — | — | US | claimed |
| WO-2018226794-A1 | AKT ISOZYME-SPECIFIC COVALENT INHIBITORS DERIVED FROM REDOX-SIGNALING LIPIDS | CORNELL UNIVERSITY (US) | 2018-12-13 | — | — | WO | claimed |
| EP-1379251-B1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | claimed |
| US-7034026-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2006-04-25 | — | — | US | claimed |
| EP-1379251-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-20040143117-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2004-07-22 | — | — | US | claimed |
| EP-1379251-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002083138-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | claimed |
| CN-122055153-A | EGFR inhibitors for treating EGFR exon 20 mutation positive lung cancer | 安塔列斯疗法股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122029161-A | Crystalline forms of PI3K inhibitors and uses thereof | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4724151-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724150-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-1379251-B1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| US-7034026-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1379251-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040143117-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2004-07-22 | — | — | US | disclosed |
| EP-1379251-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002083138-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148682-A1 | AKT ISOZYME-SPECIFIC COVALENT INHIBITORS DERIVED FROM REDOX-SIGNALING LIPIDS | AKT1, ROS1, AKT3 | AKT1 1/4885AKT2 4/4885L3MBTL1 1608/4885 |
| US-20040143117-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885L3MBTL1 2879/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | AKT1 9/4885AKT2 1/4885L3MBTL1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.